Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:19 PM ET 8-K
Financial Results Lincoln Educational Services Corp LINC

Lincoln Educational Services Financial Results

Lincoln Educational Services reported strong Q3 2026 results with revenue increasing 12.6% to $159.2 million and student starts growing 14.2%. The company also announced a $30 million increase to its share repurchase authorization and the acquisition of its Melrose Park campus property for $18.8 million.

Term
Q3 2026

“During the third quarter, we generated double-digit growth across all our key metrics, highlighted by our 14.2% increase in student starts. The strong starts reflect our organization’s flexibility and responsiveness to a dynamic marketing environment where we continue to see robust demand for our high return-on-investment training and education programs.”

Scott Shaw, President & CEO
4:19 PM ET 8-K
Financial Results Surrozen, Inc. SRZN

Surrozen Financial Results

Surrozen reported Q3 2026 financial results and announced the expansion of its Phase 2a DUET study for SZN-8141 from 60 to 150 patients. The company strengthened its balance sheet in October 2026 by closing a $95.1 million private placement tranche and raising $29.8 million via its ATM program, extending its cash runway into 2029.

Term
Q3 2026

“We have made important progress advancing Surrozen into its next stage of development, with the first patient dosed in the SZN-8141 DUET study and plans to significantly expand Phase 2a enrollment from approximately 60 to 150 patients. The additional capital raised in October positions us to generate a more robust clinical dataset across a broader DME population, while maintaining anticipated cash runway into 2029.”

Craig Parker, President and Chief Executive Officer
4:19 PM ET 10-Q
Financial Results Lucid Group, Inc. LCID

Lucid Group Q3 2026 Results: Net Loss of $831M, Loss Narrows

Lucid Group, Inc. filed its Q3 2026 report showing 396,252,830 shares of Class A common stock outstanding as of November 3, 2026. The filing highlights ongoing expansion of manufacturing facilities in Arizona (AMP-1) and Saudi Arabia (AMP-2), alongside the issuance of various convertible senior notes due in 2026, 2030, and 2031.

Key figure
Net loss $831M
4:19 PM ET 8-K
Financial Results Bitgo Holdings, Inc. BTGO

Bitgo Holdings Financial Results

BitGo Holdings reported Q3 2026 financial results with net income of $44.1 million, driven by digital asset treasury appreciation. The company completed the acquisition of NYDIG’s institutional trading business and repurchased $24.7 million of its common stock during the quarter.

Term
Q3 2026

“During the third quarter, we continued to strengthen BitGo’s position as a leading institutional digital asset infrastructure platform. We expanded our global footprint and completed the acquisition of NYDIG’s institutional trading business. We also expanded our off-exchange settlement network through partnerships and integrations with leading exchanges and liquidity providers.”

Mike Belshe, CEO of BitGo
4:19 PM ET 10-Q
Financial Results International Money Express, Inc. IMXI

International Money Express Q3 2026 Results: Net Income $4.33M, Down 12.9% YoY

International Money Express, Inc. reported 30,219,586 shares of common stock outstanding as of November 4, 2026. The filing highlights a pending acquisition of the Company by The Western Union Company, which is a primary focus of management's forward-looking statements and risk factors. Total cash and cash equivalents increased to $211.2 million as of September 30, 2026, compared to $168.7 million at the end of 2025.

Key figure
Net income $4.33M · -12.9% YoY
4:18 PM ET 8-K
Financial Results ImageneBio, Inc. IMA

ImageneBio Financial Results

ImageneBio reported third quarter 2026 financial results, ending the period with $126.6 million in cash and marketable securities. The company highlighted the continued progress of its Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis and plans to initiate a Phase 2 study in alopecia areata by year-end 2026.

“We are advancing our trials, developing a robust data set that we believe could demonstrate olevaprubart’s disease-modifying potential and tolerability profile across inflammatory indications. Our safety database continues to grow as we progress, and we are gaining experience across biologic- and JAK-experienced patients as well as those that are naïve to advanced therapies.”

Kristin Yarema, Ph.D., chief executive officer of Imagene

“With ADAPTIVE on course for topline data in the fourth quarter of 2027 and our alopecia areata trial on track to begin by year end, we are executing with capital discipline, and we are poised to deliver data that could demonstrate the true value potential of oleva.”

Kristin Yarema, Ph.D., chief executive officer of Imagene
4:18 PM ET 10-Q
Financial Results Hims & Hers Health, Inc. HIMS ▶ Call

Hims & Hers Health Q3 2026 Results: Net Loss of $33M

Hims & Hers Health, Inc. reported a net loss of $33.0 million for the third quarter of 2026, a significant decline from a net income of $15.8 million in the prior year period, despite revenue growing to $890.4 million. The company's balance sheet shows a substantial increase in goodwill and intangible assets, reflecting significant acquisition activity during the first nine months of the year.

Key figure
Net loss $33M
4:18 PM ET 10-Q
Financial Results Turning Point Brands, Inc. TPB ▶ Call

Turning Point Brands Q3 2026 Results: Net Income $3.93M, Down 81.4% YoY

Turning Point Brands reported net sales of $151.1 million for the third quarter of 2026, a significant increase from $119.0 million in the prior year. However, operating income for the quarter fell to $9.9 million from $25.9 million due to a substantial rise in selling, general, and administrative expenses.

Key figure
Net income $3.93M · -81.4% YoY
4:18 PM ET 10-Q
Financial Results GeneDx Holdings Corp. WGS

GeneDx Holdings Q3 2026 Results: Net Loss of $12.3M, Loss Widens

For the nine months ended September 30, 2026, GeneDx reported total revenue of $339.8 million, an 11% increase year-over-year, though net loss widened significantly to $93.4 million due to a $31.3 million impairment loss and increased SG&A expenses. The company strengthened its balance sheet by securing $146.0 million in long-term debt proceeds while repaying its previous Perceptive debt facility.

Key figure
Net loss $12.3M
4:18 PM ET 10-Q
Financial Results Greystone Housing Impact Investors LP GHI ▶ Call

Greystone Housing Impact Investors Q3 2026 Results: Net Income $3.19M, Up 274.3% YoY

Greystone Housing Impact Investors LP reported 23,493,038 Beneficial Unit Certificates outstanding as of September 30, 2026. The filing details various financing structures including the 2024 PFA Securitization Transaction and the use of a $200 million shelf registration statement for future capital raising.

Key figure
Net income $3.19M · +274.3% YoY
4:18 PM ET 10-Q
Financial Results Hawthorn Bancshares, Inc. HWBK

Hawthorn Bancshares Q3 2026 Results: Net Income $7.06M, Up 15.2% YoY

Hawthorn Bancshares reported net income of $20.1 million for the first nine months of 2026, up from $17.6 million in the prior year period, driven by higher net interest income. Total assets grew to $2.1 billion following an acquisition that contributed $26.0 million in goodwill and $16.3 million in common stock issuance.

Key figure
Net income $7.06M · +15.2% YoY
4:18 PM ET 8-K
Financial Results Atea Pharmaceuticals, Inc. AVIR

Atea Pharmaceuticals Financial Results

Atea Pharmaceuticals reported Q3 2026 financial results and provided a clinical update on its Phase 3 C-BEYOND trial for Hepatitis C, which met its primary and secondary endpoints. The company also secured up to $200 million in non-dilutive funding from Hercules Capital and expects topline results from its Phase 3 C-FORWARD trial in early 2027.

Term
Q3 2026

“The C-BEYOND results are strong and reinforce our conviction that the regimen of BEM/RZR will deliver a differentiated profile, including high HCV cure rates, short treatment duration, a low risk of drug-drug interactions and no food effect, which we believe are critical to drive broad adoption of BEM/RZR in clinical practice by prescribers.”

Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals

“We anticipate the upcoming topline Phase 3 results of C-FORWARD should further validate the potential of BEM/RZR, if approved, to be a new pan-genotypic treatment option for prescribers to treat people living with HCV.”

Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals
4:18 PM ET 10-Q
Financial Results Alta Equipment Group Inc. ALTG ▶ Call

Alta Equipment Group Q3 2026 Results: Net Loss of $11.5M, Loss Narrows

Alta Equipment Group reported a decrease in total assets from $1,336.3 million at year-end 2025 to $1,299.3 million as of September 30, 2026, alongside an increase in accumulated deficit to $277.0 million. The company maintains an accelerated filer status and reported 32,833,236 shares of common stock outstanding as of November 5, 2026.

Key figure
Net loss $11.5M
4:17 PM ET 10-Q
Financial Results Mesa Laboratories Inc MLAB ▶ Call

Mesa Laboratories Q2 2026 Results: Net Income $4.34M, Up 75.3% YoY

Mesa Laboratories reported Q2 2027 revenues of $31.6 million, a slight increase from $30.1 million in the prior year period. Net income for the quarter was $0.97 million ($0.16 per share), down from $1.63 million ($0.16 per share) in the same quarter last year, reflecting shifts in segment performance across sterilization, biopharmaceutical, and clinical genomics units.

Key figure
Net income $4.34M · +75.3% YoY
4:17 PM ET 10-Q
Financial Results Affiliated Managers Group, Inc. AMG

Affiliated Managers Group Q3 2026 Results: Net Income $173M, Down 18.4% YoY

Affiliated Managers Group reported a net income (controlling interest) of $469.6 million for the nine months ended September 30, 2026, an increase from $369.0 million in the prior year period. Consolidated revenue grew to $1,780.8 million for the same period, while the company significantly increased its share repurchases, totaling $782.0 million year-to-date.

Key figure
Net income $173M · -18.4% YoY
4:17 PM ET 8-K
Financial Results Lineage, Inc. LINE

Lineage Financial Results

Lineage, Inc. reported third-quarter 2026 financial results with total revenue of $1,361 million and a GAAP net loss of $173 million. The company noted stabilizing core business trends but lowered its full-year 2026 guidance due to headwinds from higher oil prices, trucking capacity constraints, and tariff uncertainty.

Term
Q3 2026

“Our core business trends continued to stabilize in the third quarter, with same-store occupancy growing year-over-year for the second consecutive quarter, further confirmation that customer inventory levels have normalized.”

Greg Lehmkuhl, president and chief executive officer of Lineage

“We expect these pressures to continue into the fourth quarter and have adjusted our guidance accordingly, but we view them as cyclical rather than a change in our trajectory. We remain confident that as these temporary pressures ease, the underlying strength of our business will become increasingly visible in our results”

Greg Lehmkuhl, president and chief executive officer of Lineage
4:17 PM ET 10-Q
Financial Results Clearway Energy LLC

Clearway Energy Q3 2026 Results: Net Income $159M, Down 53.9% YoY

Clearway Energy LLC reported a significant increase in net income for the nine months ended September 30, 2026, reaching $95 million compared to a net loss of $56 million in the prior year period. Total operating revenues grew to $1.36 billion, driven by portfolio expansions and acquisitions, while total assets increased to $17.3 billion as of September 30, 2026.

Key figure
Net income $159M · -53.9% YoY
4:17 PM ET 8-K
Financial Results FreightCar America, Inc. RAIL

FreightCar America Financial Results

FreightCar America reported Q3 2026 revenues of $76.5 million and railcar deliveries of 662 units, reflecting a challenging period compared to the prior year. Despite lower production, the company saw 65% growth in aftermarket revenue and a 28% increase in backlog value to $284.5 million. Management reaffirmed its full-year 2026 guidance for revenue and Adjusted EBITDA.

Term
Q3 2026

“While our third quarter results reflect a challenging period for the business, they were consistent with the preliminary figures we reported in October. We continued to make progress on our commercial priorities, with order intake through the first nine months exceeding our total for all of 2025 and backlog value up 28% year over year.”

Nick Randall, President and Chief Executive Officer

“Our balance sheet remains solid, with no borrowings under our revolving credit facility. Our cost structure has improved, and our aftermarket business is contributing a growing share of our results.”

Mike Riordan, Chief Financial Officer
4:17 PM ET 10-Q
Financial Results Bank7 Corp. BSVN

Bank7 Q3 2026 Results: Net Income $10.2M, Down 5.9% YoY

Bank7 Corp. reported net income of $30.6 million for the nine months ended September 30, 2026, a slight decrease from $32.3 million in the prior year period. Total assets grew to $2.01 billion, driven by a modest increase in the loan portfolio and cash balances, while shareholders' equity rose to $273.7 million.

Key figure
Net income $10.2M · -5.9% YoY
4:17 PM ET 10-Q
Financial Results Webtoon Entertainment Inc. WBTN

Webtoon Entertainment Q3 2026 Results: Net Loss of $8.37M, Loss Narrows

WEBTOON Entertainment Inc. filed its 10-Q for the period ending September 30, 2026, reporting 135,783,781 shares of common stock outstanding as of October 30, 2026. The filing highlights the company's focus on its global web-comic and web-novel ecosystem, including key platforms like LINE MANGA, NAVER SERIES, and Wattpad, while identifying as an accelerated filer.

Key figure
Net loss $8.37M
4:17 PM ET 10-Q
Financial Results Ethan Allen Interiors Inc ETD

Ethan Allen Interiors Q1 2026 Results: Net Income $1.68M, Down 83.9% YoY

Ethan Allen Interiors Inc. reported net sales of $129.6 million for the first quarter of fiscal 2027, a decrease from $147.0 million in the prior year period. Net income declined significantly to $1.7 million compared to $10.5 million, primarily driven by lower sales volume and a substantial $92.2 million cash dividend payment during the quarter.

Key figure
Net income $1.68M · -83.9% YoY
4:17 PM ET 10-Q
Financial Results Structure Therapeutics Inc. GPCR

Structure Therapeutics Q3 2026 Results: Net Loss of $145M, Loss Widens

Structure Therapeutics is a large accelerated filer reporting a limited operating history with significant operating losses and four product candidates currently in clinical development: aleniglipron, ACCG-2671, ACCG-3535, and LTSE-2578. As of October 31, 2026, the company had 214,771,065 ordinary shares outstanding and expects to require substantial additional capital to fund future operations.

Key figure
Net loss $145M
4:17 PM ET 10-Q
Financial Results Rocket Lab Corp RKLB

Rocket Lab Q3 2026 Results: Net Loss of $79.7M, Loss Widens

Rocket Lab reported total revenues of $267.8 million for the quarter ended September 30, 2026, a significant increase from $155.1 million in the prior year. Despite the revenue growth, the company recorded a net loss of $79.7 million for the quarter, driven by increased research and development costs and a $27.3 million loss on the extinguishment of debt.

Key figure
Net loss $79.7M
4:17 PM ET 10-Q
Financial Results Ferguson Enterprises Inc. FERG

Ferguson Enterprises Q3 2026 Results: Net Income $598M, Down 6.3% YoY

Ferguson Enterprises Inc. reported net sales of $9,026 million for the three months ended September 30, 2026, an increase from $8,245 million in the prior year period. Operating profit for the nine-month period rose to $2,390 million compared to $2,193 million in 2025, while the company completed the acquisition of FloWorks on August 31, 2026.

Key figure
Net income $598M · -6.3% YoY
4:17 PM ET 10-Q
Financial Results Myomo, Inc. MYO

Myomo Q3 2026 Results: Net Loss of $4.23M, Loss Widens

For the nine months ended September 30, 2026, Myomo, Inc. reported revenue of $34.1 million, a 15.5% increase compared to the same period in 2025. While the company reduced its operating loss to $7.1 million from $11.6 million year-over-year, it still recorded a net loss of $11.3 million due to significant non-cash charges related to the change in fair value of derivative liabilities.

Key figure
Net loss $4.23M
4:16 PM ET 10-Q
Financial Results Attovia Therapeutics, Inc. ATTO

Attovia Therapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Widens

Attovia Therapeutics is an emerging growth company focused on developing product candidates ATTO-1310, ATTO-2306, and ATTO-1091 for inflammatory and pruritic diseases. As of October 31, 2026, the company had 45,712,536 shares of common stock outstanding and continues to incur significant operating losses with no product revenue generated to date.

Key figure
Net loss $22.3M
4:16 PM ET 8-K
Financial Results HF Foods Group Inc. HFFG

HF Foods Group Financial Results

HF Foods Group reported third quarter 2026 net revenue of $319.6 million, a 4.1% increase year-over-year, marking its seventh consecutive quarter of growth. The company reported a GAAP net loss of $4.2 million, impacted by higher fuel costs and professional fees related to its acquisition of Searay Foods and debt refinancing. Management highlighted the successful integration of Searay Foods, representing the company's first expansion outside the United States.

Term
Q3 2026

“Our third quarter results reflect solid top line growth, marking our seventh consecutive quarter of year-over-year net revenue growth, even as industry-wide fuel costs continued to weigh on operating expenses.”

Felix Lin, President and Chief Executive Officer of HF Foods

“We are actively managing through this pressure by taking actions to mitigate the impact, and the efficiency programs built through our transformation continue to help offset higher costs.”

Felix Lin, President and Chief Executive Officer of HF Foods
4:16 PM ET 10-Q
Financial Results Definium Therapeutics, Inc. DFTX ▶ Call

Definium Therapeutics Q3 2026 Results: Net Loss of $51M, Loss Narrows

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based treatments like DT120 (LSD) and DT402 (MDMA) for psychiatric disorders. As of November 2, 2026, the company had 136,899,935 common shares outstanding and is currently conducting Phase 3 clinical programs for generalized anxiety disorder and major depressive disorder.

Key figure
Net loss $51M
4:16 PM ET 10-Q
Financial Results Clearway Energy, Inc. CWEN

Clearway Energy Q3 2026 Results: Net Income $51M, Down 78.0% YoY

Clearway Energy reported total operating revenues of $1,357 million for the first nine months of 2026, up from $1,119 million in 2025. While net income for the nine-month period improved to $85 million compared to a loss in the prior year, net income attributable to Clearway Energy, Inc. decreased significantly to $10 million due to higher allocations to noncontrolling interests.

Key figure
Net income $51M · -78.0% YoY
4:16 PM ET 10-Q
Financial Results ImageneBio, Inc. IMA

ImageneBio Q3 2026 Results: Net Loss of $15.6M, Loss Narrows

ImageneBio, Inc. (formerly Ikena Oncology) is a clinical-stage biopharmaceutical company focused on developing olevaprubart for immunological and inflammatory indications following its 2025 merger with Legacy Inmagene. As of October 31, 2026, the company had 12,456,281 shares of common stock outstanding and expects to incur significant losses for the foreseeable future while requiring substantial additional funding.

Key figure
Net loss $15.6M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.